North America Narcolepsy Therapeutics Market Size, Share & Industry Trends Analysis Report By Type, By Product (Sodium Oxybate, Selective Serotonin Reuptake Inhibitor, Central Nervous System Stimulants, Tricyclic Antidepressants), By Country and Growth Fo

North America Narcolepsy Therapeutics Market Size, Share & Industry Trends Analysis Report By Type, By Product (Sodium Oxybate, Selective Serotonin Reuptake Inhibitor, Central Nervous System Stimulants, Tricyclic Antidepressants), By Country and Growth Forecast, 2022 – 2028

The North America Narcolepsy Therapeutics Market would witness market growth of 9.8% CAGR during the forecast period (2022-2028).

There are two different forms of narcolepsy recognized by the International Classification of Sleep Disorders-Third Edition diagnostic criteria: type 1 and type 2. Chronic daily extreme sleepiness lasting less than three months, mean sleep latency of fewer than eight minutes, and two or more sleep-onset rapid eye movements on the Multiple Sleep Latency Test are all criteria that all types share. The cataplexy and/or low levels of hypocretin 1 in the cerebrospinal fluid (CSF) are additional diagnostic criteria for NT1 (orexin A).

The NT2 criteria include the absence of cataplexy, normal or unmeasured levels of hypocretin 1 in the CSF and the absence of any other condition (including medication side effects or discontinuation) that could explain the results of the EDS and/or MSLT. Many people who have narcolepsy also have unsteady, interrupted sleep, which can include frequent nighttime awakenings. The daily activities of narcoleptics can be affected. People who have narcolepsy may unintentionally nod off while engaging in activities like talking, eating, or driving.

The treatment for sleep disorders is in greater demand in both the United States and Canada. The market is expected to be driven by the rising prevalence of narcoleptic disorders, higher awareness, and high healthcare spending. The other elements projected to support revenue growth include favorable reimbursement regulations for treatments, a solid clinical pipeline, and rising stress levels. The high frequency of narcolepsy in industrialized nations like the United States would encourage more people to use narcolepsy treatments, fueling the expansion of this market.

The US market dominated the North America Narcolepsy Therapeutics Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $1,071.6 million by 2028.The Canada market is poised to grow at a CAGR of 12.3% during (2022 - 2028). Additionally, The Mexico market would witness a CAGR of 11.3% during (2022 - 2028).

Based on Type, the market is segmented into Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy. Based on Product, the market is segmented into Sodium Oxybate, Selective Serotonin Reuptake Inhibitor, Central Nervous System Stimulants, Tricyclic Antidepressants and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Jazz Pharmaceuticals plc, Shionogi & Co., Ltd., Teva Pharmaceuticals Industries Ltd., Pfizer, Inc. (Arena Pharmaceuticals, Inc.), Bioprojet, Takeda Pharmaceutical Company Limited, Ligand Pharmaceuticals, Inc., and Graymark Healthcare, Inc.

Scope of the Study

Market Segments covered in the Report:

By Type

  • Narcolepsy with Cataplexy
  • Narcolepsy Without Cataplexy
  • Secondary Narcolepsy
By Product
  • Sodium Oxybate
  • Selective Serotonin Reuptake Inhibitor
  • Central Nervous System Stimulants
  • Tricyclic Antidepressants
  • Others
By Country
  • US
  • Canada
  • Mexico
  • Rest of North America
Companies Profiled
  • Jazz Pharmaceuticals plc
  • Shionogi & Co., Ltd.
  • Teva Pharmaceuticals Industries Ltd.
  • Pfizer, Inc. (Arena Pharmaceuticals, Inc.)
  • Bioprojet
  • Takeda Pharmaceutical Company Limited
  • Ligand Pharmaceuticals, Inc.
  • Graymark Healthcare, Inc.
Unique Offerings from KBV Research
  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free


Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Narcolepsy Therapeutics Market, by Type
1.4.2 North America Narcolepsy Therapeutics Market, by Product
1.4.3 North America Narcolepsy Therapeutics Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition & scenarios
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. North America Narcolepsy Therapeutics Market by Type
3.1 North America Narcolepsy with Cataplexy Market by Country
3.2 North America Narcolepsy Without Cataplexy Market by Country
3.3 North America Secondary Narcolepsy Market by Country
Chapter 4. North America Narcolepsy Therapeutics Market by Product
4.1 North America Sodium Oxybate Market by Country
4.2 North America Selective Serotonin Reuptake Inhibitor Market by Country
4.3 North America Central Nervous System Stimulants Market by Country
4.4 North America Tricyclic Antidepressants Market by Country
4.5 North America Others Market by Country
Chapter 5. North America Narcolepsy Therapeutics Market by Country
5.1 US Narcolepsy Therapeutics Market
5.1.1 US Narcolepsy Therapeutics Market by Type
5.1.2 US Narcolepsy Therapeutics Market by Product
5.2 Canada Narcolepsy Therapeutics Market
5.2.1 Canada Narcolepsy Therapeutics Market by Type
5.2.2 Canada Narcolepsy Therapeutics Market by Product
5.3 Mexico Narcolepsy Therapeutics Market
5.3.1 Mexico Narcolepsy Therapeutics Market by Type
5.3.2 Mexico Narcolepsy Therapeutics Market by Product
5.4 Rest of North America Narcolepsy Therapeutics Market
5.4.1 Rest of North America Narcolepsy Therapeutics Market by Type
5.4.2 Rest of North America Narcolepsy Therapeutics Market by Product
Chapter 6. Company Profiles
6.1 Jazz Pharmaceuticals plc
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Regional Analysis
6.1.4 Research & Development Expenses
6.1.5 Recent strategies and developments:
6.1.5.1 Partnerships, Collaborations, and Agreements:
6.1.5.2 Approvals and Trials:
6.2 Shionogi & Co., Ltd.
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Research & Development Expenses
6.3 Teva Pharmaceutical Industries Ltd.
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Regional Analysis
6.3.4 Research & Development Expenses
6.4 Pfizer, Inc. (Arena Pharmaceuticals, Inc.)
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Regional & Segmental Analysis
6.4.4 Research & Development Expense
6.5 Bioprojet
6.5.1 Company Overview
6.5.2 Recent strategies and developments:
6.5.2.1 Partnerships, Collaborations, and Agreements:
6.6 Takeda Pharmaceutical Company Limited
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Regional Analysis
6.6.4 Research & Development Expense
6.7 Ligand Pharmaceuticals, Inc.
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Research & Development Expenses
6.8 Graymark Healthcare, Inc.
6.8.1 Company Overview

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings